Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

1. Whole brain radiotherapy provides little benefit for lung cancer that has spread

Whole brain radiotherapy provides little benefit for lung cancer that has spread Signal - Whole brain radiotherapy provides little benefit for lung cancer that has spread Dissemination Centre Discover Portal NIHR DC Discover Whole brain radiotherapy provides little benefit for lung cancer that has spread Published on 10 January 2017 Radiotherapy to the whole brain makes little difference to people with the commonest type of lung cancer that has spread to the brain and cannot be operated (...) on. This mainly UK-based trial found no difference in overall survival and quality of life among people who had whole brain radiotherapy plus usual supportive care compared with people who received supportive care alone. This is the largest trial to assess the effect of this treatment in people with non-small cell lung cancer and multiple brain metastases (cancer deposits in the brain). Practice has been changing since early results of the trial were released. The final results reinforce the message

NIHR Dissemination Centre2019

2. Postoperative radiotherapy reduces survival after surgery to remove non-small cell lung cancer

Postoperative radiotherapy reduces survival after surgery to remove non-small cell lung cancer Signal - Postoperative radiotherapy reduces survival after surgery to remove non-small cell lung cancer Dissemination Centre Discover Portal NIHR DC Discover Postoperative radiotherapy reduces survival after surgery to remove non-small cell lung cancer Published on 28 February 2017 Postoperative radiotherapy increases the risk of death by 18% for patients with non-small cell lung cancer that has been (...) on survival and cancer recurrence rates. Most of the trials are from over 30 years ago, so there is the possibility that newer radiotherapy techniques may be less harmful. Nevertheless, this review provides the best evidence to date that postoperative radiotherapy may not be appropriate as a routine treatment for non-small cell lung cancer. Share your views on the research. Why was this study needed? Lung cancer is the second most common cancer in the UK with 37,453 new cases registered in 2014

NIHR Dissemination Centre2019

3. Circulating high sensitivity C reactive protein concentrations and risk of lung cancer: nested case-control study within Lung Cancer Cohort Consortium.

Circulating high sensitivity C reactive protein concentrations and risk of lung cancer: nested case-control study within Lung Cancer Cohort Consortium. OBJECTIVES: To conduct a comprehensive analysis of prospectively measured circulating high sensitivity C reactive protein (hsCRP) concentration and risk of lung cancer overall, by smoking status (never, former, and current smokers), and histological sub-type. DESIGN: Nested case-control study. SETTING: 20 population based cohort studies in Asia (...) , Europe, Australia, and the United States. PARTICIPANTS: 5299 patients with incident lung cancer, with individually incidence density matched controls. EXPOSURE: Circulating hsCRP concentrations in prediagnostic serum or plasma samples. MAIN OUTCOME MEASURE: Incident lung cancer diagnosis. RESULTS: A positive association between circulating hsCRP concentration and the risk of lung cancer for current (odds ratio associated with a doubling in hsCRP concentration 1.09, 95% confidence interval 1.05

BMJ2019

4. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic non-small cell lung cancer

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic non-small cell lung cancer 1 Special Article Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small cell lung cancer; a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS Authors Y-L. Wu 1 , D. Planchard 2 , S. Lu 3 , H. Sun 4 , N. Yamamoto 5 , D-W. Kim 6 , D. S. W. Tan 7 , J. C-H. Yang 8 , M. Azrif 9 , T. Mitsudomi 10 , K. Park 11 , R (...) . A. Soo 12 , J.W.C. Chang 13 , A. Alip 14 , S. Peters 15 , J-Y. Douillard 16 Affiliations 1 Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, P.R. China; 2 Department of Medical Oncology, Thoracic Group, Gustave Roussy, Villejuif, France; 3 Shanghai Chest Hospital, Shanghai, P.R. China; 4 Guangdong Lung Cancer Institute, Guangdong Lung Cancer Institute, Guangdong General Hospital, School of Medicine, South China University of Technology

European Society for Medical Oncology2019

5. Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer

Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer P Pembrolizumab with pemetre embrolizumab with pemetrex xed and ed and platinum chemother platinum chemotherap apy for untreated, y for untreated, metastatic, non-squamous non-small-cell metastatic, non-squamous non-small-cell lung cancer lung cancer T echnology appraisal guidance Published: 10 January 2019 nice.org.uk/guidance/ta557 © NICE 2019. All rights reserved (...) -small-cell lung cancer (TA557) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 23Contents Contents 1 Recommendations 4 2 Information about pembrolizumab combination 6 3 Committee discussion 7 Clinical management 7 Clinical evidence 8 Indirect treatment comparisons 9 Cost effectiveness 11 Innovation 16 End of life 17 Conclusion 18 Cancer Drugs Fund 18 4 Implementation 20 5 Recommendations for data collection 21

National Institute for Health and Clinical Excellence - Technology Appraisals2019

6. ASTRO Guideline on Palliative Radiation Therapy for Non-small Cell Lung Cancer (NSCLC) - Update

ASTRO Guideline on Palliative Radiation Therapy for Non-small Cell Lung Cancer (NSCLC) - Update Practical Radiation Oncology Email/Username: Password: Remember me Search Terms Search within Search Share this page: Copyright © 2019 Inc. All rights reserved. | | | | | | The content on this site is intended for health professionals. We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the . Advertisements on this site do not constitute

American Society for Radiation Oncology2019

7. Low-dose computed tomography for lung cancer screening in high-risk populations: a systematic review and economic evaluation

Low-dose computed tomography for lung cancer screening in high-risk populations: a systematic review and economic evaluation Low-dose computed tomography for lung cancer screening in high-risk populations: a systematic review and economic evaluation Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search (...) above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Low-dose CT screening may be effective in reducing lung cancer mortality, but there is considerable uncertainty around effectiveness and value. {{author}} {{($index , , , , , , & . Tristan Snowsill 1, * , Huiqin Yang 1 , Ed Griffin 1 , Linda Long 1 , Jo Varley-Campbell 1 , Helen Coelho 1 , Sophie Robinson 1 , Chris Hyde 1, 2 1 Peninsula Technology Assessment

NIHR HTA programme2018

8. Lorlatinib (Lorbrena) - To treat patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer

Lorlatinib (Lorbrena) - To treat patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer Drug Approval Package: LORBRENA (lorlatinib) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: LORBRENA (lorlatinib) Company: Pfizer, Inc. Application Number: 210868 Approval Date: 11/02/2018 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter

FDA - Drug Approval Package2018

9. Brigatinib (Alunbrig) - non-small cell lung cancer (NSCLC)

Brigatinib (Alunbrig) - non-small cell lung cancer (NSCLC) 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. EMA/674777/2018 EMEA/H/C/004248 Alunbrig (brigatinib) An overview of Alunbrig and why it is authorised in the EU What (...) is Alunbrig and what is it used for? Alunbrig is a cancer medicine that is used to treat adults with a type of lung cancer called non-small cell lung cancer (NSCLC) who have been treated before with a cancer medicine called crizotinib. Alunbrig is used on its own and only if the NSCLC is ‘ALK-positive’, which means that the cancer cells have certain changes affecting the gene that makes a protein called ALK (anaplastic lymphoma kinase). Alunbrig contains the active substance brigatinib. How is Alunbrig

European Medicines Agency - EPARs2018

10. Patient Navigation Models for Lung Cancer

Patient Navigation Models for Lung Cancer Rapid Evidence Product Patient Navigation Models for Lung Cancer eRapid Evidence Product Patient Navigation Models for Lung Cancer Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2017-00003-C Prepared by: Scientific Resource Center Portland, OR Investigators: Jennifer Gilbert, M.D., M.P.H. Stephanie Veazie, M.P.H. Kevin Joines, B.S (...) , other quality enhancement tools, or reimbursement or coverage policies, may not be stated or implied. Persons using assistive technology may not be able to fully access information in this report. For assistance contact epc@ahrq.hhs.gov. Suggested citation: Gilbert J, Veazie S, Joines K, Winchell K, Relevo R, Paynter R, Guise J-M. Patient Navigation Models for Lung Cancer. Rapid Evidence Product. (Prepared by Scientific Resource Center under Contract No. 290-2017-00003-C.) AHRQ Publication No. 18(19

Effective Health Care Program (AHRQ)2018

11. Delivering best practice lung cancer care - a guide for health professionals

Delivering best practice lung cancer care - a guide for health professionals This guide provides an overview of the Lung Cancer Framework, which can be accessed at: canceraustralia.gov.au/publications-and-resources/cancer-australia-publications/lung-cancer-framework A summary for health professionals Delivering best practice lung cancer care Cancer Australia’s Lung Cancer Framework: Principles for Best Practice Lung Cancer Care in Australia (the Lung Cancer Framework) is a national resource (...) for health professionals and service providers involved in the care and treatment of people affected by lung cancer. canceraustralia.gov.au The Lung Cancer Framework aims to improve the outcomes and experiences of people affected by lung cancer in Australia by supporting the uptake of five key principles in lung cancer care. Principles for best practice lung cancer care Cancer Australia’s Principles for best practice management of lung cancer in Australia have been informed by evidence from national

Cancer Australia2018

12. 30-day mortality after the start of systemic anticancer therapy for lung cancer: is it really a useful performance indicator?

30-day mortality after the start of systemic anticancer therapy for lung cancer: is it really a useful performance indicator? 30406123 2018 11 14 2312-0541 4 4 2018 Oct ERJ open research ERJ Open Res 30-day mortality after the start of systemic anticancer therapy for lung cancer: is it really a useful performance indicator? 00030-2018 10.1183/23120541.00030-2018 Systemic treatment is the standard treatment for unresectable stage III and IV lung cancer. Nevertheless, a 5-10% death rate has been (...) described within 30 days after the last systemic treatment, suggesting that these patient did not benefit. We analysed the 30-day mortality after start of systemic therapy. Data were retrieved from the Netherlands National Cancer Registry. From 2010 to 2015, 26 277 patients were included. 56% were men. The median age was 65 years and 31% of patients were aged ≥70 years. 27% involved small cell lung cancer and 73% nonsmall cell lung cancer. Overall mortality within 30 days after the start of systemic

ERJ open research2018 Full Text: Link to full Text with Trip Pro

13. Metastatic Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Metastatic Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up CLINICAL PRACTICE GUIDELINES Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up † D. Planchard 1 , S. Popat 2 , K. Kerr 3 , S. Novello 4 ,E.F.Smit 5 , C. Faivre-Finn 6 ,T.S.Mok 7 , M. Reck 8 , P. E. Van Schil 9 , M. D. Hellmann 10 & S. Peters 11 , on behalf of the ESMO Guidelines Committee * 1 Department of Medical Oncology (...) : clinicalguidelines@esmo.org † Approved by the ESMO Guidelines Committee: February 2002, last update September 2018. This publication supersedes the previously published version—Ann Oncol 2016; 27 (Suppl 5): v1–v27. Incidenceandepidemiology Primary lung cancer remains the most common malignancy after non-melanocytic skin cancer, and deaths from lung cancer ex- ceed those from any other malignancy worldwide [1]. In 2012, lung cancer was the most frequently diagnosed cancer in males with an estimated 1.2 million

European Society for Medical Oncology2018

14. Bevacizumab (Mvasi) - Metastatic Colorectal Cancer (mCRC) or Locally Advanced, Metastatic or Recurrent Non-small Cell Lung Cancer (NSCLC)

Bevacizumab (Mvasi) - Metastatic Colorectal Cancer (mCRC) or Locally Advanced, Metastatic or Recurrent Non-small Cell Lung Cancer (NSCLC) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Summary Basis of Decision (SBD) for Contact: Summary basis of decision (SBD) documents provide information related to the original authorization of a product. The for is located

Health Canada - Drug and Health Product Register2018

15. Durvalumab (Imfinzi) - non-small cell lung cancer (NSCLC)

Durvalumab (Imfinzi) - non-small cell lung cancer (NSCLC) 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. EMA/521637/2018 EMEA/H/C/004771 Imfinzi (durvalumab) An overview of Imfinzi and why it is authorised in the EU What (...) is Imfinzi and what is it used for? Imfinzi is a medicine used to treat a type of lung cancer called non-small cell lung cancer (NSCLC). Imfinzi is used in adult patients with advanced cancer that cannot be removed by surgery but is not getting worse after treatment with radiation and platinum-based chemotherapy (medicines to treat cancer). Imfinzi is used specifically when the tumour produces a protein known as PD-L1. Imfinzi contains the active substance durvalumab. How is Imfinzi used? Imfinzi

European Medicines Agency - EPARs2018

16. Lung Cancer Screening

Lung Cancer Screening New 2018 ACR Appropriateness Criteria ® 1 Lung Cancer Screening American College of Radiology ACR Appropriateness Criteria ® Lung Cancer Screening Variant 1: Lung cancer screening. Patient 55 to 80 years of age and 30 or more packs per year smoking history and currently smoke or have quit within the past 15 years. Procedure Appropriateness Category Relative Radiation Level CT chest without IV contrast screening Usually Appropriate ??? CT chest with IV contrast Usually (...) Not Appropriate ??? CT chest without and with IV contrast Usually Not Appropriate ??? FDG-PET/CT skull base to mid-thigh Usually Not Appropriate ???? MRI chest without and with IV contrast Usually Not Appropriate O MRI chest without IV contrast Usually Not Appropriate O Radiography chest Usually Not Appropriate ? Variant 2: Lung cancer screening. Patient 50 years of age or older and 20 or more packs per year history of smoking and one additional risk factor (ie, radon exposure or occupational exposure

American College of Radiology2018

17. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study 30262187 2018 09 28 1474-5488 2018 Sep 21 The Lancet. Oncology Lancet Oncol. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. S1470-2045(18)30673-9 10.1016/S1470-2045(18)30673-9 Antibodies targeting the immune checkpoint molecules PD (...) -1 or PD-L1 have demonstrated clinical efficacy in patients with metastatic non-small-cell lung cancer (NSCLC). In this trial we investigated the efficacy and safety of avelumab, an anti-PD-L1 antibody, in patients with NSCLC who had already received platinum-based therapy. JAVELIN Lung 200 was a multicentre, open-label, randomised, phase 3 trial at 173 hospitals and cancer treatment centres in 31 countries. Eligible patients were aged 18 years or older and had stage IIIB or IV or recurrent NSCLC

EvidenceUpdates2018

18. Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial

Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial 30262574 2018 10 05 1399-3003 52 4 2018 Oct The European respiratory journal Eur. Respir. J. Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial. 1801220 10.1183/13993003.01220-2018 The anti-tumour and anti-metastatic properties of heparins have not been tested in patients with early stage cancer. Whether adjuvant (...) low molecular weight heparin (LMWH) tinzaparin impacts the survival of patients with resected non-small cell lung cancer (NSCLC) was investigated.Patients with completely resected stage I, II or IIIA NSCLC were randomly allocated to receive subcutaneous tinzaparin 100 IU·kg -1 once a day for 12 weeks or no treatment in addition to standard of care. The trial was open-label with blinded central adjudication of study outcomes. The primary outcome was overall survival.In 549 patients randomised to tinzaparin (n=269

EvidenceUpdates2018

19. Atezolizumab (non-small cell lung cancer) ? Benefit assessment according to §35a Social Code Book V

Atezolizumab (non-small cell lung cancer) ? Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Atezolizumab (nicht kleinzelliges Lungenkarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 27 December 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports (...) – Commission No. A17-50 Atezolizumab (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-50 Version 1.0 Atezolizumab (non-small cell lung cancer) 27 December 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Atezolizumab (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V Commissioning agency

Institute for Quality and Efficiency in Healthcare (IQWiG)2018

20. CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer 30153097 2018 08 28 1527-7755 2018 Aug 28 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell (...) Lung Cancer. JCO2018783118 10.1200/JCO.2018.78.3118 Purpose We report CNS efficacy of osimertinib versus standard epidermal growth factor receptor ( EGFR) tyrosine kinase inhibitors (TKIs) in patients with untreated EGFR-mutated advanced non-small-cell lung cancer from the phase III FLAURA study. Patients and Methods Patients (N = 556) were randomly assigned to osimertinib or standard EGFR-TKIs (gefitinib or erlotinib); brain scans were not mandated unless clinically indicated. Patients

EvidenceUpdates2018